Precompetitive consortium approach to validation of the next generation of biomarkers in schizophrenia

Biomarkers in Medicine

Volumn 8, Issue 1, 2014, Pages 5-8

  Dourish, Colin T ^a   Dawson, Gerard R ^a  

^a P1VITAL   (United Kingdom)

Author keywords

amisulpride; biomarkers; cognition; consortium; fMRI; ketamine; nicotine; risperidone; schizophrenia; schizotypy

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BIOLOGICAL MARKER; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; RISPERIDONE; SEROTONIN 7 RECEPTOR;

ANHEDONIA; DELUSION; DIABETES MELLITUS; DRUG EFFICACY; DYSKINESIA; HALLUCINATION; HUMAN; OBESITY; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER; TREATMENT OUTCOME; WORKING MEMORY;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; HUMANS; KETAMINE; MAGNETIC RESONANCE IMAGING; NICOTINE; RISPERIDONE; SCHIZOPHRENIA;

EID: 84890687207     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.89     Document Type: Review

References (17)

1. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209-1223 (2005
2. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr. Opin. Endocrinol. Diabetes Obes. 17, 460-466 (2010
3. Lewis DA, Lieberman JA. Catching up on schizophrenia: Natural history and neurobiology. Neuron 28, 325-34 (2000
4. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: Efficacy, safety and cost outcomes of CATIE and other trials. J. Clin. Psychiatry 68, e04 (2007
5. Nuechterlein KH, Green MF, Kern RS et al. The MATRICS consensus cognitive battery, part 1: Test selection, reliability, and validity. Am. J. Psychiatry 165, 203-213 (2008
6. Barch DM. Pharmacological strategies for enhancing cognition in schizophrenia. Curr. Top. Behav. Neurosci. 4, 43-96 (2010
7. Green MF, Nuechterlein KH, Gold JM et al. Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria. Biol. Psychiatry 56, 301-307 (2004
8. Hurko O. The uses of biomarkers in drug development. Ann. NY Acad. Sci. 1180, 1-10 (2009
9. Dawson GR, Craig KJ, Dourish CT. Validation of experimental medicine methods in psychiatry: The P1vital approach and experience. Biochem. Pharmacol. 81, 1435-1441 (2011
10. Raine A. Schizotypal personality: Neurodevelopmental and psychosocial trajectories. Ann. Rev. Clin. Psychol. 2, 291-326 (2006
11. Smyrnis N, Avramopoulos D, Evdokimidis I et al. Effect of schizotypy on cognitive performance and its tuning by COMT val158 met genotype variations in a large population of young men. Biol. Psychiatry 61, 845-853 (2007
12. Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214 (1994
13. Koychev I, McMullen K, Lees J et al. A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: A three-centre double-blind placebo-controlled study. Eur. Neuropsychopharmacol. 22, 469-481 (2012
14. Schmechtig A, Lees J, Grayson L et al. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy. Psychopharmacology 227(2), 331-345 (2013
15. Schmechtig A, Lees J, Perkins A et al. The effects of ketamine and risperidone on eye movement control in healthy volunteers. Transl. Psychiatry (2013) (In Press
16. Gooding DC, Basso MA. The tell-Tale tasks: A review of saccadic research in psychiatric patient populations. Brain Cogn. 68, 371-390 (2008
17. Corlett PR, Honey GD, Aitken MR et al. Frontal responses during learning predict vulnerability to the psychotogenic effects of ketamine: Linking cognition, brain activity and psychosis. Arch. Gen. Psychiatry 63, 611-621 (2006